Discovering New Benefits From Old Drugs With Big Data-Promise for Parkinson Disease

Abby L Olsen^{1

2

3}, Trond Riise^{1

4}, Clemens R Scherzer^{1

2

3

5

6}

Affiliations

¹ Precision Neurology Program, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
⁴ Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
⁵ Neurogenomics Laboratory, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
⁶ Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts.

Editorial

Abby L Olsen et al. JAMA Neurol. 2018.

. 2018 Aug 1;75(8):917-920.

doi: 10.1001/jamaneurol.2018.0345.

Abby L Olsen^{1

2

3}, Trond Riise^{1

4}, Clemens R Scherzer^{1

2

3

5

6}

¹ Precision Neurology Program, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
⁴ Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
⁵ Neurogenomics Laboratory, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
⁶ Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts.

No abstract available

Comment on

Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, Wang A. Peter I, et al. JAMA Neurol. 2018 Aug 1;75(8):939-946. doi: 10.1001/jamaneurol.2018.0605. JAMA Neurol. 2018. PMID: 29710331 Free PMC article.